CD7 and acute myeloid leukemia: Nevertheless, candidate antigens of AML, such as CD7 (50), CD33 (24), CD38 (51), CD44v6 (52), CD70 (53), CD123 (25), Siglec-6 (54), CLL1 (55), FLT3 (56), FRβ (57), Le-Y (58), NKG2D ligands (59), and some towards T cell malignancies, like CD7 (60), CD5 (61), CCR9 (62), have been utilized to constructed CAR-T cells and demonstrated the efficacy in preclinical studies.